WO2002008179A1 - Aryl sulfonamides as serotonin antagonist for the treatment of obesity - Google Patents

Aryl sulfonamides as serotonin antagonist for the treatment of obesity Download PDF

Info

Publication number
WO2002008179A1
WO2002008179A1 PCT/SE2001/001652 SE0101652W WO0208179A1 WO 2002008179 A1 WO2002008179 A1 WO 2002008179A1 SE 0101652 W SE0101652 W SE 0101652W WO 0208179 A1 WO0208179 A1 WO 0208179A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkoxy
hydroxy
formula
group
Prior art date
Application number
PCT/SE2001/001652
Other languages
French (fr)
Inventor
Patrizia Caldirola
Sukhwinder Jossan
Kjell S. Sakariassen
Jan Svartengren
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ523158A priority Critical patent/NZ523158A/en
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Priority to KR1020037000687A priority patent/KR100828977B1/en
Priority to DE60124717T priority patent/DE60124717T2/en
Priority to CA002411195A priority patent/CA2411195A1/en
Priority to DK01950200T priority patent/DK1301475T3/en
Priority to JP2002514088A priority patent/JP2004504377A/en
Priority to EP01950200A priority patent/EP1301475B1/en
Priority to AU7122501A priority patent/AU7122501A/en
Priority to AU2001271225A priority patent/AU2001271225B2/en
Publication of WO2002008179A1 publication Critical patent/WO2002008179A1/en
Priority to NO20030297A priority patent/NO20030297L/en
Priority to HK04100767A priority patent/HK1057886A1/en
Priority to CY20071100214T priority patent/CY1106026T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the use of aryl sulfonamide compounds, active as 5-HT 6 receptor antagonists, in the treatment of obesity.
  • Obesity is a condition characterized in an increase in body fat content resulting in excess body weight above accepted norms. Obesity is the most important nutritional disorder in the western world and represents a major health problem in all industrialized countries. This disorder leads to increased mortality due to increased incidences of diseases such as cardiovascular disease, digestive disease, respiratory disease, cancer and NTDDM (type II diabetes). Searching for compounds, which reduce body weight has been going on for many decades.
  • One line of research has been activation of serotonergic systems, either by direct activation of serotonin receptor subtypes or by inhibiting serotonin reuptake. The exact receptor subtype profile required is however not known.
  • Serotonin (5-hydroxytryptamine or 5-HT), a key transmitter of the peripheral and central nervous system, modulate a wide range of physiological and pathological functions, including anxiety, sleep regulation, aggression, feeding and depression.
  • 5-HT6 receptor Multiple serotonin receptor subtypes have been identified and cloned.
  • 5-HT6 receptor was cloned by several groups in 1993 (M Ruat, E Traiffort, J-M
  • This receptor is positively coupled to adenylyl cyclase and displays affinity for antidepressants such as clozapine.
  • Aryl sulfonamide compounds have been disclosed as possessing 5-HT 6 receptor activity and being useful in the treatment of CNS disorders (EP 815861). Further classes of aryl sulfonamide compounds with 5-HT 6 receptor activity have been reported in WO 98/27081 and WO 99/42465. The compounds are believed to be of potential use in the treatment of certain CNS disorders.
  • the object of the present invention is to present an improved method of treatment of obesity.
  • a further object is a new use of compounds for the manufacture of medicaments for obesity treatment.
  • SB-271046 (5-Chloro-3-methyl-benzo-[b]thiophene-2-sulphonic acid (4- methoxy-3-piperazin ⁇ yl-phenyl)-amide monohydrochloride) on food intake in ob/ob mice.
  • mCPP m-chloro-phenylpiperazine
  • a method of treatment or prophylaxis of obesity in mammals including humans comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I) or formula (JJ)
  • E is -SO 2 NH- or -NHSO 2 -;
  • R 2 is hydrogen, C 1-6 alkyl or arylC 1-6 alkyl;
  • P is phenyl, naphthyl a bicyclic heterocyclic ring or is a 5- to 7-membered heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur;
  • A is a single bond, a C ⁇ alkylene or a C ⁇ _ 6 alkenylene group;
  • R 1 is halogen, C 1-6 alkyl, optionally substituted by one or more halogen atoms,
  • C 3-6 cycloalkyl COC 1-6 alkyl, C 1-6 alkoxy, OCF 3 , hydroxy, hydroxy C 1-6 alkyl, hydroxy C 1-6 alkoxy, C ⁇ -6 alkoxy C 1-6 alkoxy, C 1-6 alkanoyl, acyl, nitro, arnino, alkylamino or dialkylamino, cyano or SR 11 where R 11 is hydrogen or C 1-6 alkyl or R 1 is phenyl, benzyl, naphthyl, a bicyclic heterocyclic ring, or is a 5 to 7-membered heterocyclic ring, each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur; n is O, 1, 2, 3, 4, 5 or 6;
  • R 3 is a group R 5 or together with R 5 forms a group (CH 2 ) 2 O or (CH 2 ) 3 O or R 3 is linked to R 2 to form a group (CH 2 ) 2 or (CH 2 ) 3 ;
  • R 4 is -X(CH 2 )p-R 6 wherein X is a single bond, CH 2 , O, NH or N-C 1-6 -alkyl; p is 0 to 6 and
  • R 6 is an optionally substituted 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from nitrogen, sulfur or oxygen, or R is NR R wherein R 7 and R 8 are independently hydrogen, C 1-6 alkyl or aryl C ⁇ -6 alkyl, or R 4 is selected from a group of formula (i), (ii) or (iii) Formula (i)
  • R 9 is C 1-6 alkyl, or C ⁇ -6 alkyl substituted by one or more halogen atoms; m is 0, 1 or 2; q is O, 1, 2, 3 or 4; or
  • R 6 , m and q are as defined in formula (i); or
  • R , m and q are as defined in formula (i) and R is hydrogen or C 1-6 alkyl;
  • R 5 is hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, optionally substituted with one or more fluorine atoms, C 3-6 cycloalkyl, COC ⁇ -6 alkyl, C 1-6 alkoxy, hydroxy, hydroxy C 1-6 alkyl, hydroxy C 1-6 alkoxy, C 1-6 alkoxyC ⁇ -6 alkoxy, acyl, nitro, trifluoromethyl or together with R 3 forms a group (CH 2 ) 2 O or (CH 2 ) 3 O, cyano or aryl.
  • R 1 is halogen, C ⁇ -6 alkyl, optionally substituted by one or more fluorine atoms, C -6 cycloalkyl, C 1-6 alkoxy, OCF 3 , C 1-6 alkoxy C 1-6 alkoxy, C 1-6 alkanoyl, amino, alkylamino or dialkylamino, SR 11 where R 11 is hydrogen or C 1-6 alkyl or R 1 is phenyl, benzyl, naphthyl, a bicyclic heterocyclic ring, or is a 5 to 7-membered heterocyclic ring, each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur; n is 0, 1, 2, 3, 4 or 5;
  • R 3 is a group R 5 or together with R 5 forms a group (CH 2 ) 2 O or (CH 2 ) 3 O;
  • R 4 is selected from a group of formula (i), (ii) or (iii) as mentioned above;
  • R 5 is hydrogen, halogen, C ⁇ -6 alkyl, C 1-6 alkoxy, optionally substituted with one or more fluorine atoms, trifluoromethyl or together with R 3 forms a group (CH 2 ) 2 O or (CH 2 ) 3 O.
  • R 1 is halogen, C 1-6 alkyl optionally substituted by one or more halogen atoms, C 3-6 cycloalkyl, COC 1-6 alkyl, C 1-6 alkoxy, OCF 3 , hydroxy, hydroxy C 1-6 alkyl, hydroxy C 1-6 alkoxy, Ci-ealkoxyCi- ⁇ alkoxy, acyl, nitro, amino, alkylamino or dialkylamino, cyano or R 1 is phenyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring, each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur;
  • R 4 is -X(CH 2 )p-R 6 where X is a single bond, CH 2 , O, NH or N-C 1-6 -alkyl and p is
  • R 6 is an optionally substituted 5- to 7-membered heterocyclic ring containing
  • R 6 is NR 7 R 8 where R 7 and R 8 are independently hydrogen, C 1-6 alkyl or aryl C 1-6 alkyl and R 5 is hydrogen, halogen, C 1-6 alkyl, C 3-6 cycloalkyl, COC 1-6 alkyl, C 1-6 alkoxy, hydroxy, hydroxy C ⁇ -6 alkyl, hydroxy Ci-ealkoxy, Ci- ⁇ alkoxyCi-ealkoxy, acyl, nitro, trifluoromethyl, cyano or aryl.
  • 5-HT 6 receptor antagonists belonging to the aryl sulfonamide compounds disclosed in WO 98/27081 and WO 99/42465, reduce food intake and body weight.
  • An improved method of treating obesity is therefore provided by the present invention.
  • alkyl groups may be straight chained or branched both alone and as part of another group.
  • Preferred alkyl groups are methyl and ethyl.
  • Halogen means a group selected from fluorine, chlorine, bromine or iodine.
  • group P is a bicyclic heterocyclic ring suitable examples include benzothienyl, indolyl, quinolinyl or isoquinolinyl.
  • P is a 5 to 7- membered heterocyclic ring
  • suitable examples include thienyl, furyl, pyrrolyl, triazolyl, diazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyrrolidinyl and pyrazinyl.
  • the heterocyclic rings can be linked to the remaining molecule via any suitable carbon atom or, when present, a nitrogen.
  • P is phenyl, naphthyl, thienyl and most preferably benzothienyl.
  • A is a single bond or methylene.
  • R 1 is halogen, or C ⁇ -6 alkyl optionally substituted by one or more halogen atoms, for example methyl or trifluoromethyl.
  • R 1 is a heterocyclic group suitable examples include those listed above for P.
  • n is 0, 1, 2 or 3, particularly 1 or 2.
  • R 2 is hydrogen or C 1- alkyl.
  • R 2 is hydrogen. It will be appreciated that when R 3 /R 5 groups are linked together the two groups must be attached to adjacent carbon atoms of the phenyl ring.
  • R 3 is a group R 5 , in particular hydrogen.
  • R4 is preferably a group:
  • R 5 is C 1-6 alkoxy, most preferably methoxy.
  • R 5 is para with respect to the sulfonamide linkage.
  • R 4 is preferably meta with respect to the sulfonamide linkage.
  • X is a bond
  • p is 0
  • R 6 is an optionally substituted 5- to 7-membered heterocyclic ring.
  • the heterocyclic rings can be linked to the remaining molecule via a carbon atom or, when present, a nitrogen atom.
  • Optional substituents for these rings, which can be present on carbon and /or nitrogen atoms, include C 1-6 alkyl, in particular methyl. More preferably R 4 is N-piperazine optionally substituted by C 1-6 alkyl, particularly unsubstituted piperazine.
  • P-A is benzo[b]thiophen-2yl or benzo[b]thiophen-3-yl optionally substituted by one or two R 1 groups, especially 5-chloro-3-methyl- benzo[2]thiophen-2-yl.
  • a particularly preferred compound of the invention is
  • the compounds of the formula (I) and (JJ) can form acid addition salts with acids such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic. tartaric and methanesulfonic.
  • acids such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic. tartaric and methanesulfonic.
  • the compounds for obesity treatment can conveniently be administered in a pharmaceutical composition containing the compound in combination with a suitable excipient.
  • a pharmaceutical composition containing the compound in combination with a suitable excipient can be prepared by methods and contain excipients which are well known in the art. A generally recognized compendium of such methods and ingredients is Remington's Pharmaceutical Sciences by E.W. Martin (Mark Publ. Co., 15 th Ed., 1975).
  • the compounds and compositions can be administered orally, parenterally (for example, by intravenous, intraperitoneal or intramuscular injection), topically, or rectally. Preferably the compounds are administered orally.
  • the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • Such compositions and preparations should contain at least 0.1% of active compound.
  • the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form.
  • the amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
  • the tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added.
  • a liquid carrier such as a vegetable oil or a polyethylene glycol.
  • any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed.
  • the active compound may be incorporated into sustained-release preparations and devices.
  • the compounds or compositions can also be administered intravenously, or intraperitoneally by infusion or injection.
  • Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils.
  • Useful dosages of the compounds of formula I can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Patent No. 4,938,949.
  • the compound can be administered in unit dosage form; for example, containing about 0.05 mg to about 500 mg, conveniently about 0.1 mg to about 250 mg, most conveniently, about 1 mg to about 150 mg of active ingredient per unit dosage form.
  • the desired dose may be presented in a single dose or as divided doses administered at appropriate intervals.
  • the compositions can be administered orally, sublingually, transdermally, or parenterally at dose levels of about 0.01 to about 150 mg/kg, preferably about 0.1 to about 50 mg/kg, and more preferably about 0.1 to about 30 mg/kg of mammal body weight.
  • Obese (ob/ob) mouse is selected as the primary animal model for screening as this mutant mouse consumes high amounts of food resulting in a high signal to noise ratio.
  • C57BL/6J mice wild type mice. The amount of food consumed during 15 hours of infusion of compounds is recorded.
  • Male mice 8-9 weeks with an average body weight of 50 g (obese) and 25 g (lean) are used in all the studies.
  • the animals are housed singly in cages at 23 ⁇ 1°C, 40-60 % humidity and have free access to water and standard laboratory chow.
  • the 12/12-h light/dark cycle is set to lights off at 5 p.m.
  • the animals are conditioned for at least one week before start of study.
  • test compounds are dissolved in solvents suitable for each specific compound such as cyclodextrin, cyclodextrin/methane sulfonic acid, polyethylene glycol/methane sulfonic acid, or saline. Fresh solutions are made for each study. Doses of 30, 50 and 100 mg kg _1 day _1 are used. The purity of the test compounds is of analytical grade.
  • Minipump implantation The animals are weighed at the start of the study and randomized based on body weight. Alzet osmotic minipumps (Model 200 ID; infusion rate 8 ⁇ l/h) are used and loaded essentially as recommended by the Alzet technical information manual (Alza Scientific Products, 1997; Teeuwes and Yam, 1976). Continuous subcutaneous infusion with 24 hours duration is used.
  • the minipumps are either filled with different concentrations of test compounds dissolved in vehicle or with only vehicle solution and maintained in vehicle pre-warmed to 37°C (approx. lh).
  • the minipumps are implanted subcutaneously in the neck/back region under short acting anesthesia (metofane/enflurane). This surgical procedure lasts approximately 5 min. It takes about 3 h to reach steady state delivery of the compound.
  • the weights of the food pellets are measured at 5 p.m. and at 8 p.m. for two days before (baseline) and one day after the implantation of the osmotic minipumps. The weighing is performed with a computer assisted Mettler Toledo PR 5002 balance. Occasional spillage is corrected for. At the end of the study the animals are killed by neck dislocation and trunk blood sampled for later analysis of plasma drug concentrations. Determination of plasma concentration
  • the plasma sample proteins are precipitated with methanol, centrifuged and the supernatant is transferred to HPLC vials and injected into the liquid chromatography /mass spectrometric system.
  • MRM Multiple Reaction Monitoring
  • a linear regression analysis of the standards forced through the origin is used to calculate the concentrations of the unknown samples.
  • Fig. 1 shows the reduction of food intake, after subcutaneous continuos infusion of test compound SB-271046 (5-Chloro-3-methyl-benzo-[b]thiophene-2-sulphonic acid (4- methoxy-3-piperazin-yl-phenyl)-amide monohydrochloride) at the dose of 10, 30 and 50 mg/kg/day.
  • the compound induced significant reduction of food intake of 45% (0.006*), 60 % (0.019*) and 77 % (0.034*) respectively compared to the basal level of food intake. *Free plasma concentration at the steady state giving the effect at the respective doses.
  • mCPP m-Chloro-phenylpiperazine

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides a method of treatment or prophylaxis of obesity, comprising administering to a patient in need of such treatment a therapeutically effective amount of an aryl sulfonamide compound of formula (I) or formula (II) wherein the substituents are as described in the specification in which E is -SO2NH- or -NHSO2.

Description

ARYL SULFONAMIDES AS SEROTONIN ANTAGONIST FOR THE TREATMENT OF OBESITY
TECHNICAL FIELD
The present invention relates to the use of aryl sulfonamide compounds, active as 5-HT6 receptor antagonists, in the treatment of obesity.
BACKGROUND ART
Obesity is a condition characterized in an increase in body fat content resulting in excess body weight above accepted norms. Obesity is the most important nutritional disorder in the western world and represents a major health problem in all industrialized countries. This disorder leads to increased mortality due to increased incidences of diseases such as cardiovascular disease, digestive disease, respiratory disease, cancer and NTDDM (type II diabetes). Searching for compounds, which reduce body weight has been going on for many decades. One line of research has been activation of serotonergic systems, either by direct activation of serotonin receptor subtypes or by inhibiting serotonin reuptake. The exact receptor subtype profile required is however not known.
Serotonin (5-hydroxytryptamine or 5-HT), a key transmitter of the peripheral and central nervous system, modulate a wide range of physiological and pathological functions, including anxiety, sleep regulation, aggression, feeding and depression. Multiple serotonin receptor subtypes have been identified and cloned. One of these, the 5-HT6 receptor, was cloned by several groups in 1993 (M Ruat, E Traiffort, J-M
Arrang, J Tardivel-Lacombe, J Diaz, R Leurs, J-C Shwartz. Biochem. Biophys. Res. Commun. 1993, 193 (1) 268-276; M Sebben, H Ansanay, J Bockaert, A Dumuis, NeuroReport 5, 2553-2557 (1994).) This receptor is positively coupled to adenylyl cyclase and displays affinity for antidepressants such as clozapine. Recently, the effect of 5-HT6 antagonist and 5-HT6 antisense oligonucleotides to reduce food intake in rats has been reported (JC Bentley, CA Mardsen, AJ Sleight and KC Fone Effect of 5- HT6 antagonist Ro 04-6790 on food consumption in rats traineds to a fixed feeding regime Br JPharmac. 1999 Suppl 126 P66; JC Bentley, AJ Sleight, CA Mardsen, KCF Fone 5~HT<5 antisense oligonucleotide ICV affects rat performance in the water maze and feeding J Psychopharmacol Suppl A64 1997 255).
Aryl sulfonamide compounds have been disclosed as possessing 5-HT6 receptor activity and being useful in the treatment of CNS disorders (EP 815861). Further classes of aryl sulfonamide compounds with 5-HT6 receptor activity have been reported in WO 98/27081 and WO 99/42465. The compounds are believed to be of potential use in the treatment of certain CNS disorders.
The object of the present invention is to present an improved method of treatment of obesity. A further object is a new use of compounds for the manufacture of medicaments for obesity treatment.
BRIEF DESCRIPTION OF THE DRAWING
Fig. 1
Effect of SB-271046 (5-Chloro-3-methyl-benzo-[b]thiophene-2-sulphonic acid (4- methoxy-3-piperazin~yl-phenyl)-amide monohydrochloride) on food intake in ob/ob mice. mCPP (m-chloro-phenylpiperazine) was used as a positive control.
SUMMARY OF THE INVENTION
The objects of the invention are achieved by the method of treatment and use of the compounds as claimed in the claims. According to the invention a method of treatment or prophylaxis of obesity in mammals including humans is provided. The method comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I) or formula (JJ)
Figure imgf000003_0001
Figure imgf000004_0001
wherein
E is -SO2NH- or -NHSO2-; R2 is hydrogen, C1-6 alkyl or arylC1-6alkyl;
P is phenyl, naphthyl a bicyclic heterocyclic ring or is a 5- to 7-membered heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur;
A is a single bond, a C^ alkylene or a Cι_6 alkenylene group; R1 is halogen, C1-6 alkyl, optionally substituted by one or more halogen atoms,
C3-6 cycloalkyl, COC1-6 alkyl, C1-6 alkoxy, OCF3, hydroxy, hydroxy C1-6alkyl, hydroxy C1-6alkoxy, Cι-6 alkoxy C1-6 alkoxy, C1-6 alkanoyl, acyl, nitro, arnino, alkylamino or dialkylamino, cyano or SR11 where R11 is hydrogen or C1-6 alkyl or R1 is phenyl, benzyl, naphthyl, a bicyclic heterocyclic ring, or is a 5 to 7-membered heterocyclic ring, each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur; n is O, 1, 2, 3, 4, 5 or 6;
R3 is a group R5 or together with R5 forms a group (CH2)2O or (CH2)3O or R3 is linked to R2 to form a group (CH2)2 or (CH2)3; R4 is -X(CH2)p-R6 wherein X is a single bond, CH2, O, NH or N-C1-6-alkyl; p is 0 to 6 and
R6 is an optionally substituted 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from nitrogen, sulfur or oxygen, or R is NR R wherein R7 and R8 are independently hydrogen, C1-6 alkyl or aryl Cι-6 alkyl, or R4 is selected from a group of formula (i), (ii) or (iii) Formula (i)
Figure imgf000005_0001
wherein R9 is C1-6alkyl, or Cι-6alkyl substituted by one or more halogen atoms; m is 0, 1 or 2; q is O, 1, 2, 3 or 4; or
Formula (ii)
Figure imgf000005_0002
wherein
R6, m and q are as defined in formula (i); or
Formula (iii)
Figure imgf000005_0003
wherein R , m and q are as defined in formula (i) and R is hydrogen or C1-6alkyl;
R5 is hydrogen, halogen, C1-6alkyl, C1-6alkoxy, optionally substituted with one or more fluorine atoms, C3-6 cycloalkyl, COCι-6 alkyl, C1-6 alkoxy, hydroxy, hydroxy C1-6alkyl, hydroxy C1-6alkoxy, C1-6alkoxyCι-6alkoxy, acyl, nitro, trifluoromethyl or together with R3 forms a group (CH2)2O or (CH2)3O, cyano or aryl. Preferably, in formula (I):
R1 is halogen, Cι-6 alkyl, optionally substituted by one or more fluorine atoms, C -6 cycloalkyl, C1-6 alkoxy, OCF3, C1-6 alkoxy C1-6 alkoxy, C1-6 alkanoyl, amino, alkylamino or dialkylamino, SR11 where R11 is hydrogen or C1-6 alkyl or R1 is phenyl, benzyl, naphthyl, a bicyclic heterocyclic ring, or is a 5 to 7-membered heterocyclic ring, each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur; n is 0, 1, 2, 3, 4 or 5;
R3 is a group R5 or together with R5 forms a group (CH2)2O or (CH2)3O;
R4 is selected from a group of formula (i), (ii) or (iii) as mentioned above; R5 is hydrogen, halogen, Cι-6alkyl, C1-6alkoxy, optionally substituted with one or more fluorine atoms, trifluoromethyl or together with R3 forms a group (CH2)2O or (CH2)3O.
Preferably, in formula (IT): R1 is halogen, C1-6alkyl optionally substituted by one or more halogen atoms, C3-6 cycloalkyl, COC1-6 alkyl, C1-6alkoxy, OCF3, hydroxy, hydroxy C1-6alkyl, hydroxy C1-6alkoxy, Ci-ealkoxyCi-όalkoxy, acyl, nitro, amino, alkylamino or dialkylamino, cyano or R1 is phenyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring, each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur;
R4 is -X(CH2)p-R6 where X is a single bond, CH2, O, NH or N-C1-6-alkyl and p is
0 to 6 and R6 is an optionally substituted 5- to 7-membered heterocyclic ring containing
1 to 3 heteroatoms selected from nitrogen, sulfur or oxygen, or R6 is NR7R8 where R7 and R8 are independently hydrogen, C1-6 alkyl or aryl C1-6 alkyl and R5 is hydrogen, halogen, C1-6 alkyl, C3-6 cycloalkyl, COC1-6 alkyl, C1-6 alkoxy, hydroxy, hydroxy Cι-6alkyl, hydroxy Ci-ealkoxy, Ci-βalkoxyCi-ealkoxy, acyl, nitro, trifluoromethyl, cyano or aryl.
The compounds of formula (I) and (JJ) can also be used in the form of pharmaceutically acceptable salts thereof. DETAILED DESCRIPTION OF THE INVENTION
According to the present invention, it has surprisingly been found that 5-HT6 receptor antagonists, belonging to the aryl sulfonamide compounds disclosed in WO 98/27081 and WO 99/42465, reduce food intake and body weight. An improved method of treating obesity is therefore provided by the present invention.
In the formulas the alkyl groups may be straight chained or branched both alone and as part of another group. Preferred alkyl groups are methyl and ethyl. "Halogen" means a group selected from fluorine, chlorine, bromine or iodine. When the group P is a bicyclic heterocyclic ring suitable examples include benzothienyl, indolyl, quinolinyl or isoquinolinyl. When P is a 5 to 7- membered heterocyclic ring suitable examples include thienyl, furyl, pyrrolyl, triazolyl, diazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyrrolidinyl and pyrazinyl. The heterocyclic rings can be linked to the remaining molecule via any suitable carbon atom or, when present, a nitrogen. Preferably P is phenyl, naphthyl, thienyl and most preferably benzothienyl. Suitably A is a single bond, a methylene or ethylene group or a -CH=CH- group. Preferably A is a single bond or methylene.
Preferably R1 is halogen, or Cι-6 alkyl optionally substituted by one or more halogen atoms, for example methyl or trifluoromethyl. When R1 is a heterocyclic group suitable examples include those listed above for P. Preferably n is 0, 1, 2 or 3, particularly 1 or 2.
Suitably R2 is hydrogen or C1- alkyl. Preferably R2 is hydrogen. It will be appreciated that when R3/R5 groups are linked together the two groups must be attached to adjacent carbon atoms of the phenyl ring. Preferably R3 is a group R5, in particular hydrogen.
In formula (I) R4 is preferably a group:
Figure imgf000008_0001
Preferably R5 is C1-6 alkoxy, most preferably methoxy. Preferably R5 is para with respect to the sulfonamide linkage. In formula (U) R4 is preferably meta with respect to the sulfonamide linkage.
Preferably X is a bond, p is 0 and R6 is an optionally substituted 5- to 7-membered heterocyclic ring. The heterocyclic rings can be linked to the remaining molecule via a carbon atom or, when present, a nitrogen atom. Optional substituents for these rings, which can be present on carbon and /or nitrogen atoms, include C1-6 alkyl, in particular methyl. More preferably R4 is N-piperazine optionally substituted by C1-6 alkyl, particularly unsubstituted piperazine.
A preferred meaning for P-A is benzo[b]thiophen-2yl or benzo[b]thiophen-3-yl optionally substituted by one or two R1 groups, especially 5-chloro-3-methyl- benzo[2]thiophen-2-yl. A particularly preferred compound of the invention is
5-chloro-N-(4-methoxy-3-piperazin-l-yl-phenyl)-3-methyl-2- benzothiophenesulf onamide..
The compounds of the formula (I) and (JJ) can form acid addition salts with acids such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic. tartaric and methanesulfonic.
Compounds of formula (I) and (II) may also form solvates such as hydrates and the invention also extends to these forms. When referred to herein, it is understood that the term "compound of formula (I) and (II)" also includes these forms. Certain compounds of formula (I) and (II) are capable of existing in stereoisomeric forms including diastereomers and enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates. The different stereoisomeric forms may be separated one from the other by the usual methods. Any given isomer may be obtained by stereospecific or asymmetric synthesis. The invention also extends to any tautomeric forms and mixtures thereof. The compounds used in the invention are prepared according to the methods described in WO 98/27081 and WO 99/42465 the contents of which are hereby included by reference.
According to the present invention the compounds for obesity treatment can conveniently be administered in a pharmaceutical composition containing the compound in combination with a suitable excipient. Such pharmaceutical compositions can be prepared by methods and contain excipients which are well known in the art. A generally recognized compendium of such methods and ingredients is Remington's Pharmaceutical Sciences by E.W. Martin (Mark Publ. Co., 15th Ed., 1975). The compounds and compositions can be administered orally, parenterally (for example, by intravenous, intraperitoneal or intramuscular injection), topically, or rectally. Preferably the compounds are administered orally.
For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.
The compounds or compositions can also be administered intravenously, or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils.
Useful dosages of the compounds of formula I can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Patent No. 4,938,949.
The compound can be administered in unit dosage form; for example, containing about 0.05 mg to about 500 mg, conveniently about 0.1 mg to about 250 mg, most conveniently, about 1 mg to about 150 mg of active ingredient per unit dosage form. The desired dose may be presented in a single dose or as divided doses administered at appropriate intervals.The compositions can be administered orally, sublingually, transdermally, or parenterally at dose levels of about 0.01 to about 150 mg/kg, preferably about 0.1 to about 50 mg/kg, and more preferably about 0.1 to about 30 mg/kg of mammal body weight.
EXAMPLE: Effect of compounds on food intake in ob/ob mice
Animals
Obese (ob/ob) mouse is selected as the primary animal model for screening as this mutant mouse consumes high amounts of food resulting in a high signal to noise ratio. To further substantiate and compare efficacy data, the effect of the compounds on food consumption is also studied in wild type (C57BL/6J) mice. The amount of food consumed during 15 hours of infusion of compounds is recorded. Male mice (obese C57BL/6JBom-Leρob and lean wild-type C57Bl/6JBom; Bomholtsgaard, Denmark) 8-9 weeks with an average body weight of 50 g (obese) and 25 g (lean) are used in all the studies. The animals are housed singly in cages at 23±1°C, 40-60 % humidity and have free access to water and standard laboratory chow. The 12/12-h light/dark cycle is set to lights off at 5 p.m. The animals are conditioned for at least one week before start of study.
Compounds
The test compounds are dissolved in solvents suitable for each specific compound such as cyclodextrin, cyclodextrin/methane sulfonic acid, polyethylene glycol/methane sulfonic acid, or saline. Fresh solutions are made for each study. Doses of 30, 50 and 100 mg kg_1day_1 are used. The purity of the test compounds is of analytical grade.
Minipump implantation The animals are weighed at the start of the study and randomized based on body weight. Alzet osmotic minipumps (Model 200 ID; infusion rate 8 μl/h) are used and loaded essentially as recommended by the Alzet technical information manual (Alza Scientific Products, 1997; Teeuwes and Yam, 1976). Continuous subcutaneous infusion with 24 hours duration is used. The minipumps are either filled with different concentrations of test compounds dissolved in vehicle or with only vehicle solution and maintained in vehicle pre-warmed to 37°C (approx. lh). The minipumps are implanted subcutaneously in the neck/back region under short acting anesthesia (metofane/enflurane). This surgical procedure lasts approximately 5 min. It takes about 3 h to reach steady state delivery of the compound.
Food intake measurements
The weights of the food pellets are measured at 5 p.m. and at 8 p.m. for two days before (baseline) and one day after the implantation of the osmotic minipumps. The weighing is performed with a computer assisted Mettler Toledo PR 5002 balance. Occasional spillage is corrected for. At the end of the study the animals are killed by neck dislocation and trunk blood sampled for later analysis of plasma drug concentrations. Determination of plasma concentration
The plasma sample proteins are precipitated with methanol, centrifuged and the supernatant is transferred to HPLC vials and injected into the liquid chromatography /mass spectrometric system. The mass spectrometer is set for electrospray positive ion mode and Multiple Reaction Monitoring (MRM with the transition m/z 316 =» 221). A linear regression analysis of the standards forced through the origin is used to calculate the concentrations of the unknown samples.
Statistical evaluation Food consumption for 15 hours is measured for the three consecutive days and the percentage of basal level values is derived for each animal from the day before and after treatment. The values are expressed as mean±SD and mean±SEM from eight animals per dose group. Statistical evaluation is performed by Kruskal-Wallis one-way ANOVA using the per cent basal values. If statistical significance is reached at the level of p<0.05, Mann- Whitney U-test for statistical comparison between control and treatment groups is performed.
Results
Fig. 1 shows the reduction of food intake, after subcutaneous continuos infusion of test compound SB-271046 (5-Chloro-3-methyl-benzo-[b]thiophene-2-sulphonic acid (4- methoxy-3-piperazin-yl-phenyl)-amide monohydrochloride) at the dose of 10, 30 and 50 mg/kg/day. The compound induced significant reduction of food intake of 45% (0.006*), 60 % (0.019*) and 77 % (0.034*) respectively compared to the basal level of food intake. *Free plasma concentration at the steady state giving the effect at the respective doses. m-Chloro-phenylpiperazine (mCPP) was used as a positive control.

Claims

1. Method of treatment or prophylaxis of obesity in mammals, including humans, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I) or formula (II)
Figure imgf000013_0001
Figure imgf000013_0002
wherein
E is -SO2NH- or -NHSO2-; R2 is hydrogen, C1-6 alkyl or arylC1-6alkyl; P is phenyl, naphthyl a bicyclic heterocyclic ring or is a 5- to 7-membered hererocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur;
A is a single bond, a C 1 _6 alkylene or a C ι - alkenylene group; R1 is halogen, C1-6 alkyl, optionally substituted by one or more halogen atoms, C3-6 cycloalkyl, COCι-6 alkyl, C1-6 alkoxy, OCF3, hydroxy, hydroxy C1-6alkyl, hydroxy C1-6alkoxy, Cι-6 alkoxy C1-6 alkoxy, C1-6 alkanoyl, acyl, nitro, amino, alkylamino or dialkylamino, cyano or SR11 where R11 is hydrogen or C1-6 alkyl or R1 is phenyl, benzyl, naphthyl, a bicyclic heterocyclic ring, or is a 5 to 7-membered heterocyclic ring, each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur; n is 0, 1, 2, 3, 4, 5 or 6; R3 is a group R5 or together with R5 forms a group (CH2)2O or (CH2)3O or R3 is linked to R2 to form a group (CH2)2 or (CH2)3;
R4 is -X(CH2)ρ-R6 where X is a single bond, CH2, 0, NH or N-C1-6-alkyl and p is
0 to 6 and R6 is an optionally substituted 5- to 7-membered heterocyclic ring containing
1 to 3 heteroatoms selected from nitrogen, sulfur or oxygen, or R is NR R where R and R8 are independently hydrogen, C1-6 alkyl or aryl C1-6 alkyl, or
R4 is selected from a group of formula (i), (ii) or (iii) Formula (i)
Figure imgf000014_0001
wherein R is C1-6alkyl, or C1-6alkyl substituted by one or more halogen atoms; m is 0, 1 or 2; q is O, 1, 2, 3 or 4; or Formula (ii)
Figure imgf000014_0002
wherein R9, m and q are as defined in formula (i); or Formula (iii)
Figure imgf000014_0003
wherein R9, m and q are as defined in formula (i) and R7 is hydrogen or Cι-6alkyl;
R5 is hydrogen, halogen, Cι-6alkyl, C1-6alkoxy, optionally substituted with one or more fluorine atoms, C3-6 cycloalkyl, COC1-6 alkyl, C1-6 alkoxy, hydroxy, hydroxy C1-6alkyl, hydroxy Cι-6alkoxy, C1-6alkoxyC1-6alkoxy, acyl, nitro, trifluoromethyl or together with R3 forms a group (CH2)2O or (CH2)3O, cyano or aryl; or pharmaceutically acceptable salts thereof.
2. The method according to claim 1 wherein:
R1 is halogen, C1-6 alkyl, optionally substituted by one or more fluorine atoms, C3-6 cycloalkyl, C1-6 alkoxy, OCF3, C1-6 alkoxy Cι-6 alkoxy, C1-6 alkanoyl, amino, alkylamino or dialkylamino, SR11 where R11 is hydrogen or C1-6 alkyl or R1 is phenyl, benzyl, naphthyl, a bicyclic heterocyclic ring, or is a 5 to 7-membered heterocyclic ring, each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur; n is O, 1, 2, 3, 4 or 5;
R is a group R or together with R forms a group (CH2)2O or (CH2)3O; R4 is selected from a group of formula (i), (ii) or (iii) as mentioned above; R5 is hydrogen, halogen, C1-6alkyl, C1-6alkoxy, optionally substituted with one or more fluorine atoms, trifluoromethyl or together with R3 forms a group (CH2) O or (CH2)3O in formula (I).
3. The method according to claim 1 wherein:
R1 is halogen, C1-6alkyl optionally substituted by one or more halogen atoms, C3-6 cycloalkyl, COC1-6 alkyl, C1-6alkoxy, OCF3, hydroxy, hydroxy C1-6alkyl, hydroxy
C1-6alkoxy, C1-6alkoxyC1-6alkoxy, acyl, nitro, amino, alkylamino or dialkylamino, cyano or R1 is phenyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring, each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur; R4 is -X(CH2)p-R6 where X is a single bond, CH2, O, NH or N-C1-6-alkyl and p is
0 to 6 and R6 is an optionally substituted 5- to 7-membered heterocyclic ring containing
1 to 3 heteroatoms selected from nitrogen, sulfur or oxygen, or R6 is NR7R8 where R7 and R8 are independently hydrogen, C1-6 alkyl or aryl C1-6 alkyl and
R5 is hydrogen, halogen, C1-6 alkyl, C3-6 cycloalkyl, COC1-6 alkyl, C1-6 alkoxy, hydroxy, hydroxy Cι-6alkyl, hydroxy Cι-6alkoxy, C1-6alkoxyC1- alkoxy, acyl, nitro, trifluoromethyl, cyano or aryl in formula (A).
4. The method according to any one of claims 1 to 3 wherein P is benzothiophene.
5. The method according to any one of claims 1 to 4 wherein R1 is halogen or Cι-6 alkyl optionally substituted with one or more halogen atoms.
The method according to any one of claims 1 to 5 wherein R2 is hydrogen.
7. The method according to any one of claims 1 to 6 wherein R4 in formula (II) is an unsubstituted piperazine ring.
8. The method according to any one of claims 1 to 7 wherein R5 is C1-6 alkoxy.
9. The method according to any one of claims 1 to 8 wherein P-A is 5-chloro-3- methyl-benzo [2] thiophen-2-yl .
10. The method according to claim 1 wherein the compound is 5-chloro-N-(4- methoxy-3-piperazin-l-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide.
11. Use of a compound of formula (I) or (JJ)
Figure imgf000016_0001
Figure imgf000016_0002
wherein
E is -SO2ΝH- or -NHSO2-; R2 is hydrogen, C1-6 alkyl or arylC1-6alkyl;
P is phenyl, naphthyl a bicyclic heterocyclic ring or is a 5- to 7-membered hererocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur; A is a single bond, a C 1 _6 alkylene or a C ^ alkenylene group;
R1 is halogen, C1-6 alkyl, optionally substituted by one or more halogen atoms, C3-6 cycloalkyl, COC1-6 alkyl, C1-6 alkoxy, OCF3, hydroxy, hydroxy C1-6alkyl, hydroxy C1-6alkoxy, C1-6 alkoxy C1-6 alkoxy, Cι-6 alkanoyl, acyl, nitro, amino, alkylamino or dialkylamino, cyano or SR11 where R11 is hydrogen or C1-6 alkyl or R1 is phenyl, benzyl, naphthyl, a bicyclic heterocychc ring, or is a 5 to 7-membered heterocyclic ring, each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur; n is O, 1, 2, 3, 4, 5 or 6;
R3 is a group R5 or together with R5 forms a group (CH )2O or (CH2)3O or R3 is linked to R2 to form a group (CH2)2 or (CH2)3; R4 is -X(CH2)ρ-R6 where X is a single bond, CH2, O, NH or N-C1-6-alkyl and p is
0 to 6 and R6 is an optionally substituted 5- to 7-membered heterocyclic ring containing
1 to 3 heteroatoms selected from nitrogen, sulfur or oxygen, or R6 is NR7R8 where R7 and R8 are independently hydrogen, C1-6 alkyl or aryl C1-6 alkyl, or
R4 is selected from a group of formula (i), (ii) or (iii) Formula (i)
Figure imgf000017_0001
wherein R9 is Cι-6alkyl, or C1-6alkyl substituted by one or more halogen atoms; m is 0, 1 or 2; q is O, 1, 2, 3 or 4; or
Formula (ii)
Figure imgf000017_0002
wherein R9, m and q are as defined in formula (i); or Formula (iii)
Figure imgf000018_0001
wherein R9, m and q are as defined in formula (i) and R7 is hydrogen or Cι-6alkyl;
R5 is hydrogen, halogen, C1-6alkyl, C1-6alkoxy, optionally substituted with one or more fluorine atoms, C3-6 cycloalkyl, COC1-6 alkyl, C1-6 alkoxy, hydroxy, hydroxy C1-6 alkyl, hydroxy C1-6 alkoxy, C1-6 alkoxy -C1-6 alkoxy, acyl, nitro, trifluoromethyl or together with R3 forms a group (CH2)2O or (CH2)3O, cyano or aryl; or pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of obesity.
12. The use according to claim 11 wherein
R1 is halogen, C1-6 alkyl, optionally substituted by one or more fluorine atoms, C3-6 cycloalkyl, C1-6 alkoxy, OCF3, Cχ-6 alkoxy Cι-6 alkoxy, C1-6 alkanoyl, amino, alkylamino or dialkylamino, SR11 where R11 is hydrogen or C1-6 alkyl or R1 is phenyl, benzyl, naphthyl, a bicyclic heterocyclic ring, or is a 5 to 7-membered heterocyclic ring, each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur; n is O, 1, 2, 3, 4 or 5;
R3 is a group R5 or together with R5 forms a group (CH2)2O or (CH2)3O; R4 is selected from a group of formula (i), (ii) or (iii) as mentioned above; R5 is hydrogen, halogen, C1-6alkyl, C1-6alkoxy, optionally substituted with one or more fluorine atoms, trifluoromethyl or together with R3 forms a group (CH2)2O or (CH2)3O in formula (I).
13. The use according to claim 11 wherein
R1 is halogen, C1-6alkyl optionally substituted by one or more halogen atoms, C3-6 cycloalkyl, COC1-6 alkyl, C1-6alkoxy, OCF3, hydroxy, hydroxy C1-6alkyl, hydroxy C1-6alkoxy, C1-6alkoxyC1-6alkoxy, acyl, nitro, amino, alkylamino or dialkylamino, cyano or R1 is phenyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring, each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur; R4 is -X(CH2)p-R6 where X is a single bond, CH2, O, NH or N-C1-6-alkyl and p is
0 to 6 and R6 is an optionally substituted 5- to 7-membered heterocyclic ring containing
1 to 3 heteroatoms selected from nitrogen, sulfur or oxygen, or R6 is NR7R8 where R7 and R8 are independently hydrogen, C1-6 alkyl or aryl C1-6 alkyl and
R5 is hydrogen, halogen, C1-6 alkyl, C3-6 cycloalkyl, COC1-6 alkyl, C1-6 alkoxy, hydroxy, hydroxy C1-6alkyl, hydroxy C1-6alkoxy, C1-6alkoxyC1-6alkoxy, acyl, nitro, trifluoromethyl, cyano or aryl in formula (II).
14. The use according to any one of claims 11 to 13 wherein P is benzothiophene.
15. The use according to any one of claims 11 to 14 wherein R1 is halogen or C1-6 alkyl optionally substituted with one or more halogen atoms.
16. The use according to any one of claims 11 to 15 wherein R2 is hydrogen.
17. The use according to any one of claims 11 to 16 wherein R4 in formula (JJ) is an unsubstituted piperazine ring.
18. The use according to any one of claims 11 to 17 wherein R5 is C1-6 alkoxy.
19. The use according to any one of claims 11 to 18 wherein P-A is 5-chloro-3- methyl-benzo[2]thiophen-2-yl.
20. The use according to claim 11 wherein the compound is: 5-chloro-N-(4-methoxy- 3 -piperazin- 1 -yl-phenyl)-3 -methyl-2-benzothiophenesulf onamide.
PCT/SE2001/001652 2000-07-21 2001-07-19 Aryl sulfonamides as serotonin antagonist for the treatment of obesity WO2002008179A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2002514088A JP2004504377A (en) 2000-07-21 2001-07-19 Aryl sulfonamides as serotonin antagonists for the treatment of obesity
KR1020037000687A KR100828977B1 (en) 2000-07-21 2001-07-19 Aryl sulfonamides as serotonin antagonist for the treatment of obesity
DE60124717T DE60124717T2 (en) 2000-07-21 2001-07-19 ARYL-SULPHONAMIDES AS SEROTONIN ANTAGONISTS FOR THE TREATMENT OF FAT ADJUSTMENT
CA002411195A CA2411195A1 (en) 2000-07-21 2001-07-19 Aryl sulfonamides as serotonin antagonist for the treatment of obesity
DK01950200T DK1301475T3 (en) 2000-07-21 2001-07-19 Arylsulfonamides, as a serotonin antagonist for the treatment of obesity
NZ523158A NZ523158A (en) 2000-07-21 2001-07-19 Aryl sulfonamides active as 5-HT6 receptor antagonist or serotonin antagonist for the treatment of obesity
EP01950200A EP1301475B1 (en) 2000-07-21 2001-07-19 Aryl sulfonamides as serotonin antagonist for the treatment of obesity
AU7122501A AU7122501A (en) 2000-07-21 2001-07-19 Aryl sulfonamides as serotonin antagonist for the treatment of obesity
AU2001271225A AU2001271225B2 (en) 2000-07-21 2001-07-19 Aryl sulfonamides as serotonin antagonist for the treatment of obesity
NO20030297A NO20030297L (en) 2000-07-21 2003-01-20 Aryl sulfonamides as serotonin antagonist for the treatment of obesity
HK04100767A HK1057886A1 (en) 2000-07-21 2004-02-06 Aryl sulfonamides as serotonin antagonist for the treatment of obesity
CY20071100214T CY1106026T1 (en) 2000-07-21 2007-02-15 ARYLSULFONAMIDES AS SEPOTONIN ANTAGONISTS FOR THE TREATMENT OF OBESITY

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002739-1 2000-07-21
SE0002739A SE0002739D0 (en) 2000-07-21 2000-07-21 New use

Publications (1)

Publication Number Publication Date
WO2002008179A1 true WO2002008179A1 (en) 2002-01-31

Family

ID=20280564

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2001/001652 WO2002008179A1 (en) 2000-07-21 2001-07-19 Aryl sulfonamides as serotonin antagonist for the treatment of obesity

Country Status (17)

Country Link
EP (1) EP1301475B1 (en)
JP (1) JP2004504377A (en)
KR (2) KR100828977B1 (en)
CN (1) CN100339073C (en)
AT (1) ATE346040T1 (en)
AU (2) AU7122501A (en)
CA (1) CA2411195A1 (en)
CY (1) CY1106026T1 (en)
DE (1) DE60124717T2 (en)
DK (1) DK1301475T3 (en)
ES (1) ES2277930T3 (en)
HK (1) HK1057886A1 (en)
NO (1) NO20030297L (en)
NZ (1) NZ523158A (en)
PT (1) PT1301475E (en)
SE (1) SE0002739D0 (en)
WO (1) WO2002008179A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072198A1 (en) * 2002-02-28 2003-09-04 Glaxo Group Limited The use of a benzenesulfonamide compound in the treatment of obesity
WO2009056632A1 (en) * 2007-11-02 2009-05-07 Abbott Gmbh & Co. Kg Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
US7759339B2 (en) 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
US8076326B2 (en) 2009-04-30 2011-12-13 Abbott Gmbh & Co. Kg N-phenyl- (piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
US8183237B2 (en) 2009-04-30 2012-05-22 Abbott Laboratories Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
US8362010B2 (en) 2009-04-30 2013-01-29 Abbott Gmbh & Co. Kg Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
WO2013087954A1 (en) * 2011-12-15 2013-06-20 Universidad De Zaragoza Compounds that inhibit beta amyloid peptide aggregation

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611003A1 (en) * 1993-02-09 1994-08-17 Merck & Co. Inc. Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity
EP0815861A1 (en) * 1996-06-28 1998-01-07 F. Hoffmann-La Roche Ag Sulphonamides and their use
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments
WO1998029411A1 (en) * 1996-12-27 1998-07-09 Knoll Aktiengesellschaft Sulfonamide compounds having 5-ht receptor activity
WO1999002502A2 (en) * 1997-07-11 1999-01-21 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
JPH11171856A (en) * 1997-09-26 1999-06-29 Fujirebio Inc Acylsulfonamide derivative
WO1999042465A2 (en) * 1998-02-18 1999-08-26 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
EP1072597A1 (en) * 1999-07-29 2001-01-31 Pfizer Limited Pyrazoles and their use as endothelin antagonists

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611003A1 (en) * 1993-02-09 1994-08-17 Merck & Co. Inc. Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity
EP0815861A1 (en) * 1996-06-28 1998-01-07 F. Hoffmann-La Roche Ag Sulphonamides and their use
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments
WO1998029411A1 (en) * 1996-12-27 1998-07-09 Knoll Aktiengesellschaft Sulfonamide compounds having 5-ht receptor activity
WO1999002502A2 (en) * 1997-07-11 1999-01-21 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
JPH11171856A (en) * 1997-09-26 1999-06-29 Fujirebio Inc Acylsulfonamide derivative
WO1999042465A2 (en) * 1998-02-18 1999-08-26 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
EP1072597A1 (en) * 1999-07-29 2001-01-31 Pfizer Limited Pyrazoles and their use as endothelin antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN *
THERESA A. BRANCHEK ET AL.: "5-HT6 receptor as emerging targets for drug discovery", ANNU. REV. PHARMACOL. TOXICOL., vol. 40, 2000, pages 319 - 334, XP002967462 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072198A1 (en) * 2002-02-28 2003-09-04 Glaxo Group Limited The use of a benzenesulfonamide compound in the treatment of obesity
US7759339B2 (en) 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2009056632A1 (en) * 2007-11-02 2009-05-07 Abbott Gmbh & Co. Kg Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
US7790727B2 (en) 2007-11-02 2010-09-07 Abbott Gmbh & Co. Kg Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
JP2011502973A (en) * 2007-11-02 2011-01-27 アボット ゲーエムベーハー ウント カンパニー カーゲー Benzenesulfonanilide compounds suitable for the treatment of disorders responsive to modulation of serotonin 5-HT6 receptors
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
US8183237B2 (en) 2009-04-30 2012-05-22 Abbott Laboratories Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
US8076326B2 (en) 2009-04-30 2011-12-13 Abbott Gmbh & Co. Kg N-phenyl- (piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
US8362010B2 (en) 2009-04-30 2013-01-29 Abbott Gmbh & Co. Kg Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2013087954A1 (en) * 2011-12-15 2013-06-20 Universidad De Zaragoza Compounds that inhibit beta amyloid peptide aggregation
ES2413911A1 (en) * 2011-12-15 2013-07-17 Universidad De Zaragoza Compounds that inhibit beta amyloid peptide aggregation

Also Published As

Publication number Publication date
PT1301475E (en) 2007-02-28
NO20030297D0 (en) 2003-01-20
CN1443161A (en) 2003-09-17
AU7122501A (en) 2002-02-05
CA2411195A1 (en) 2002-01-31
ATE346040T1 (en) 2006-12-15
EP1301475A1 (en) 2003-04-16
JP2004504377A (en) 2004-02-12
CY1106026T1 (en) 2011-04-06
EP1301475B1 (en) 2006-11-22
KR20080016725A (en) 2008-02-21
NZ523158A (en) 2004-04-30
KR100880806B1 (en) 2009-01-30
DK1301475T3 (en) 2007-04-02
DE60124717D1 (en) 2007-01-04
HK1057886A1 (en) 2004-04-23
DE60124717T2 (en) 2007-09-13
CN100339073C (en) 2007-09-26
ES2277930T3 (en) 2007-08-01
AU2001271225B2 (en) 2006-09-07
KR20030016413A (en) 2003-02-26
KR100828977B1 (en) 2008-05-13
SE0002739D0 (en) 2000-07-21
NO20030297L (en) 2003-01-20

Similar Documents

Publication Publication Date Title
KR100386229B1 (en) Inhibition of smooth muscle migration and proliferation of hydroxycarbazole compounds
EP1450806B1 (en) Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake
EP1438045B1 (en) Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake
EP1301475B1 (en) Aryl sulfonamides as serotonin antagonist for the treatment of obesity
AU2001271225A1 (en) Aryl sulfonamides as serotonin antagonist for the treatment of obesity
AU779696B2 (en) Methods for treating apnea and apnea disorders using optically pure R(+)ondansetron
WO2006000222A2 (en) The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
US6399617B1 (en) Use
JP2003501462A (en) Receptor agonists and antagonists
EP1064944A1 (en) Protein kinase N inhibitor comprising Fasudil
Graul et al. Tegaserod Maleate< Prop INNM
US6410565B1 (en) α1-adrenergic receptor antagonists
US20030139424A1 (en) Use
AU707892B2 (en) Methods of inhibiting colon tumors
AU2003220743B2 (en) Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
EP1435238A1 (en) Methods for treating apnea and apnea disorders using optically pure R (+) ondansetron
MXPA97002861A (en) Method to inhibit the conditions associated with bradicin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001950200

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2411195

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 523158

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001271225

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 62/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020037000687

Country of ref document: KR

Ref document number: 1020037000683

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 018131506

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020037000687

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1020037000683

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020037000683

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001950200

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 523158

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 523158

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001950200

Country of ref document: EP